Últimas noticias sobre K Wave Media (NASDAQ:KWM) Bolsa

K Wave Media Ltd is a company formed for the purpose of entering into a business combination agreement.

K Wave Media Ltd

RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) has outperformed the market over the past 5 years by 5.31% on an annualized basis producing an average annual return of 19.7%. Currently, RTX has a market capitalization of $195.25 billion. 
Buying $1000 In RTX: If an investor had bought $1000 of RTX stock 5 years ago, it would be worth $2,521.77 today based on a price of $146.15 for RTX at the time of writing.
<h3>RTX's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751902213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In RTX 5 Years Ago Would Be Worth Today

<a href="https://www.bloomberg.com/news/articles/2025-07-07/russia-s-crude-production-stayed-below-opec-target-in-june" title="https://www.bloomberg.com/news/articles/2025-07-07/russia-s-crude-production-stayed-below-opec-target-in-june">https://www.bloomberg.com/news/articles/2025-07-07/russia-s-crude-production-stayed-below-opec-target-in-june</a>

Macro Economic Events

Global

Economics

'Russia's Crude Production Stayed Below OPEC+ Target in June' - Bloomberg News

WIIM

Top KingWin shares are trading lower after the company announced it terminated its $1.52 million securities purchase agreement and rescinds its 3.5 million share transaction.

Barclays analyst Mathieu Robilliard maintains TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) with a Equal-Weight and raises the price target from $17.5 to $20.

Price Target

Analyst Ratings

TIMB

Barclays Maintains Equal-Weight on TIM, Raises Price Target to $20

<a href="https://www.cnbc.com/2025/07/07/robinhood-stock-tokens-face-scrutiny-in-the-eu-after-openai-warning.html?&amp;qsearchterm=robinhood" title="https://www.cnbc.com/2025/07/07/robinhood-stock-tokens-face-scrutiny-in-the-eu-after-openai-warning.html?&amp;qsearchterm=robinhood">https://www.cnbc.com/2025/07/07/robinhood-stock-tokens-face-scrutiny-in-the-eu-after-openai-warning.html?&amp;qsearchterm=robinhood</a>

Legal

HOOD

'Robinhood stock tokens face scrutiny in the European Union after OpenAI warning' - CNBC

Barclays analyst Benjamin Theurer maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Equal-Weight and raises the price target from $61 to $64.

Barclays Maintains Equal-Weight on Nutrien, Raises Price Target to $64

As Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) prepares to unveil its fiscal third-quarter results on Tuesday, market watchers are bracing for a pivotal moment that could shape the company&#8217;s trajectory for <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46212313/penguin-solutions-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">the remainder of the year.</a>
The company is likely to report its results broadly in line with expectations, with a low-teens sequential decline in revenue, according to Stifel.
The Penguin Solutions Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8cb85e9300015f1add/brian-chin">Analyst Brian Chin</a> reaffirmed a Buy rating and price target of $27.
The Penguin Solutions Thesis: The Advanced Computing segment is expected to grow by more than 20% in fiscal 2025, driven by customer and product expansion as well as the company's "expanded go-to-market strategy, Chin said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"If further upside were to materialize, we suspect it could come from Integrated Memory given strength in pricing and signs of some +demand inflection," he wrote.
Penguin Solutions could report revenues of $325.0 million and earnings of 31 cents per share, versus a consensus of $328.1 million and 32 cents per share, respectively, the analyst stated.
The company could project top- and bottom-line of $345.0 million and 33 cents per share for the fiscal fourth quarter, versus current consensus of $339.0 million and 30 cents per share, respectively, he added.
PENG Price Action: Penguin Solutions shares were up 1.05% at $21.09 at the time of publication Monday, <a href="https://pro.benzinga.com/">according to Benzinga Pro.</a>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46276421/broadcom-tesla-mag-7-switch-musk-trump-feud">Musk Chaos Could Oust Tesla From Mag 7, Making Way For Broadcom</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Previews

Reiteration

Movers

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions Q3 Preview: Revenue May Slip, But 1 Segment Could Surprise

Barclays analyst Benjamin Theurer maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Overweight and raises the price target from $40 to $46.

Barclays Maintains Overweight on Mosaic, Raises Price Target to $46

Barclays analyst Benjamin Theurer maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Overweight and raises the price target from $48 to $49.

Barclays Maintains Overweight on FMC, Raises Price Target to $49

AIFU

AIFU shares are trading lower after the company announced a $31.6 million non-brokered private placement.

Barclays analyst Benjamin Theurer maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Equal-Weight and raises the price target from $70 to $75.

CTVA

Barclays Maintains Equal-Weight on Corteva, Raises Price Target to $75

Barclays analyst Benjamin Theurer maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Equal-Weight and raises the price target from $91 to $95.

Barclays Maintains Equal-Weight on CF Industries Holdings, Raises Price Target to $95

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is back in the headlines, this time with a volatile combination of sagging fundamentals and political drama fueling the narrative. The electric vehicle behemoth delivered a dismal year-over-year delivery decline in company history days before CEO Elon Musk took to social media platform X to announce the creation of a new political party— the America Party.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46253926/tesla-nvidia-palantir-etfs-dominate-as-traders-pile-into-high-risk-bets-in-june">Tesla, Nvidia, Palantir ETFs Dominate As Traders Pile Into High-Risk Bets In June</a>
The twin developments have unsettled investors and is looming like a dark cloud over a <a href="https://www.benzinga.com/etfs">series of ETFs</a> with significant Tesla holdings. Some ETFs are tracking Tesla&#8217;s fortunes directly; others are pegged to the broader consumer or electric car industries. A closer examination of the most vulnerable ETFs follows, along with how they&#8217;re responding:
<h2 class="wp-block-heading">ETF Exposure: Who&#8217;s Feeling The Musk Effect Most?</h2>
Simplify Volt TSLA Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TESL#NYSE">TESL</a>)
Tesla Weighting: ~50%
Characteristic: Extremely volatile; mirrors TSLA&#8217;s fluctuations
TESL is a high-conviction Tesla-targeted ETF, designed to surf, or withstand, the Tesla tsunami. It feeds on Tesla&#8217;s innovation story, with autonomy and AI. But in 2025, that trust is being challenged. Amid delivery downtrends and political curveballs, the fund has been finding it difficult to gain traction.
The stock crashed more than 7% today morning.
Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)
Tesla Weighting: ~16% (second-largest position behind Amazon)
Characteristic: Deteriorating in recent weeks
As Tesla marches, so does XLY, at least to some degree. The ETF&#8217;s emphasis on large U.S. consumer discretionary players makes it vulnerable to Tesla&#8217;s performance, particularly considering the carmaker&#8217;s size in the index. Weak deliveries are a structural blow, and Musk&#8217;s volatile behavior introduces narrative risk.
The stock is down more than 1.1% in the early hours of regular trading today.
Vanguard Consumer Discretionary ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCR#NYSE">VCR</a>)
Tesla Weighting: between 12–16%
Characteristic: Slightly in the red after paring April&#8217;s losses
VCR gives wider exposure through the consumer discretionary universe but is still top-heavy in Tesla. It is less sensitive than TESL or XLY but still susceptible to any persistent underperformance in the EV sector or changes in consumer demand sentiment.
The stock is down 1.2% in the morning trading hours today.
<h2 class="wp-block-heading">Tesla&#8217;s Sharp YoY Global Vehicle Delivery Decline</h2>
Tesla sold 384,122 vehicles in Q2 2025, 13.5% lower than a year ago and less than the 387,000 expected by analysts, according to FactSet. Production was also lower, at 410,244 vehicles for the quarter. The decrease was strongest in the Model 3/Y platform, indicating loss of traction in Tesla&#8217;s mainstay products.
With Chinese electric vehicle manufacturers launching competitively priced, regularly updated models, Tesla is now confronted with a tougher global EV battlefield. Its image is also taking a beating in the midst of CEO Musk&#8217;s divisive public image and political activism.
<h2 class="wp-block-heading">Robotaxi: Hope On The Horizon Or Just Hype?</h2>
One silver lining: Tesla&#8217;s much-hyped robotaxi fleet is finally on the road in Austin, Texas. A small number of autonomous Model Y vehicles are currently running, with more extensive rollouts planned later this year. 
Nonetheless, investors are split. Regulation obstacles, safety doubts, and technical implementation issues may hold back the rollout. For Tesla-biased ETFs, the robotaxi play is a high-risk, high-reward swing.
<h2 class="wp-block-heading">Musk&#8217;s Political Pivot: A New Party, A New Problem</h2>
As if it wasn&#8217;t complicated enough to navigate the EV space, Musk has ventured into American politics. The America Party, which was announced on X following a poll of his followers, is positioned as an anti-establishment option. But the political foray has spooked Tesla observers and ETF issuers alike.
Case in point: the Azoria Tesla Convexity ETF, which was supposed to debut with a strategy targeting Tesla stock and options, <a href="https://www.benzinga.com/etfs/new-etfs/25/07/46268650/musks-political-ambition-derail-tesla-etf-launch-by-azoria-partners-elon-left-us-with-no-other-choice">has been put on hold indefinitely</a>. Azoria CEO James Fishback pointed to Musk&#8217;s political distraction and incendiary timing as top red flags for institutional investors.
Tesla stock fell more than 7% today morning, as Wall Street is attempting to determine how Musk&#8217;s political aspirations will impact his day job(s).
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46267743/tesla-shares-fall-over-5-in-overnight-trading-as-elon-musk-jumps-back-into-politics">Tesla Shares Fall Over 5% In Overnight Trading As Elon Musk Jumps Back Into Politics</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Tech

ETFs

TESL

TSLA

Select Sector SPDR-Consumer Discretionary

Tesla Troubles Amplified By Musk's Party Politics: ETFs On Edge

Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is currently experiencing a decline in its stock price, trading lower on Monday. The company&#8217;s stock has plummeted approximately 18% over the past month, reflecting recent challenges.
A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) ended its collaboration with Hims &amp; Hers. Consequently, Hims &amp; Hers will no longer have direct access to Wegovy, Novo Nordisk&#8217;s popular GLP-1 weight-loss drug, through the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46050799/hims-hers-health-stock-is-tumbling-monday-whats-happening" rel="noreferrer noopener">NovoCare Pharmacy</a>.
Novo Nordisk stated in a press release that the termination was due to Hims &amp; Hers Health&#8217;s alleged failure to adhere to laws prohibiting mass sales of compounded drugs under the false guise of &#8220;personalization&#8221; and its use of deceptive marketing practices, which Novo Nordisk claimed disregarded patient safety.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can&#8217;t Afford Long-Term Use: &#8216;Coverage Is Not The Same As Access,&#8217; Says Expert</a>
This split represents the latest challenge facing Hims &amp; Hers, even as the company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030.
Hims &amp; Hers Health shares are under pressure largely because the firm sells cheaper, compounded versions of popular weight-loss drugs. Regulators typically permit compounded versions of drugs to enter the market to meet demand when there&#8217;s an official shortage of the brand-name product.
However, the FDA announced earlier this year that semaglutide, the active ingredient in Wegovy, had been removed from the drug shortage list, indicating that supply was now sufficient to meet current and projected demand. This change had a notable impact on Hims &amp; Hers.
Despite this, the company reported significant success in its GLP-1 offerings, generating over <a target="_blank" href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening" rel="noreferrer noopener">$225 million in revenue</a> in 2024 from these products. The ongoing legal and regulatory scrutiny now centers on the legality of mass-producing compounded versions once the official shortage is declared over.
Morgan Stanley, in a Monday note, highlighted an &#8220;increased focus on both the legal and business implications that could influence the stock.&#8221; Analysts spoke with two experts to gain insight into these implications, particularly concerning Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">lawsuits against compounders</a>.
Analyst Craig Hettenbach says that Expert #1 cautiously advised compounding pharmacies to cease large-scale production of GLP-1 drugs once the shortage ends, acknowledging that business owners have varying levels of risk tolerance.
Expert #2 offered a more nuanced perspective, suggesting there might be a legitimate case for compounding GLP-1s under 503A for specific patient groups, even if the drugs are not individually tailored. Nevertheless, Expert #2 admitted that little legal precedent supports this view and believed that merely adding a vitamin to a GLP-1 would likely not render the product legally compliant under 503A, a common practice among some compounders.
Both experts indicated that even if the current cases are dismissed, Eli Lilly could refile with stronger arguments. Presently, the compounders are seeking dismissal of the lawsuits, contending that Eli Lilly, as a private company, cannot make certain claims that fall solely under the FDA&#8217;s jurisdiction.
The two experts discussed whether it would be helpful to ask for a preliminary injunction, a court order to stop the compounders from operating during the case. Expert #2 thinks it will be hard for Lilly to get one because the company would need to prove it&#8217;s suffering serious, irreversible harm.
Without that injunction, the compounders can keep running their businesses while the cases are ongoing. Both experts stressed that each case depends heavily on the specific facts, so gathering evidence and going through the legal process will take time. A final decision in these cases will probably take 2 to 3 years.
In light of these developments, Morgan Stanley has maintained its Equal Weight rating on Hims &amp; Hers Health, with <a target="_blank" href="https://www.benzinga.com/quote/HIMS/analyst-ratings" rel="noreferrer noopener">a price forecast of $40</a>.
Earlier in June, the company announced a significant step in its global expansion through its agreement to acquire ZAVA, a <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45779301/hims-hers-zava-acquisition-deal-expands-its-market-opportunity-by-52-billion-analyst" rel="noreferrer noopener">digital health platform in Europe</a>.
The strategic move will expand Hims &amp; Hers&#8217; footprint in the United Kingdom and officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.
Price Action: HIMS stock is trading lower by 5.51% to $45.38 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance" target="_blank" rel="noreferrer noopener">Molina Healthcare Says Higher Medical Cost Trends Bite, Cuts Profit Guidance</a></li>
</ul>
Image by T. Schneider via Shutterstock

Biotech

Large Cap

Health Care

General

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits

FLYE

Fly-E Group Shares Resume Trade

Wells Fargo analyst Ken Gawrelski maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and raises the price target from $100 to $120.

UBER

Wells Fargo Maintains Overweight on Uber Technologies, Raises Price Target to $120

A man who had been quietly juggling <a href="https://www.benzinga.com/personal-finance/entrepreneurship/25/06/46074452/juggling-multiple-high-paying-jobs-seemed-like-a-dream-until-the-guilt-kicked-in-it-felt-bad-to-constantly-lie-to-my-coworkers">several high-paying</a> remote jobs says he made a huge mistake: he told his dad. Now, he fears the secret getting out could cost him everything.
<h2 class="wp-block-heading">He Told His Dad. His Dad Told Everyone Else.</h2>
Posting on Reddit&#8217;s <a href="https://www.reddit.com/r/overemployed/comments/1lqfmn5/never_tell_your_parents_ever/">r/Overemployed</a> forum, the man shared how his father unintentionally blew his cover. &#8220;Told my dad, and he mentioned it to some of his friends at an event,&#8221; he wrote. &#8220;Obviously he was saying it with pride like &#8216;my son makes XX a year doing OE.'&#8221;
But things quickly spiraled. One of his dad&#8217;s friends shared the info with their own adult child. And during a game night at the original poster&#8217;s house, that person dropped a bomb in front of everyone: &#8220;How are you broke if you work five different jobs?&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a></li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
That moment, he said, &#8220;outed me in front of everyone. Now I&#8217;m anxious as those people might tell even more people. It&#8217;s a domino effect and I hate it.&#8221;
Although he hasn&#8217;t been caught by any employer yet, he said the damage is done: &#8220;I feel like the grenade trigger has been pulled and it&#8217;s only a matter of time now.&#8221;
<h2 class="wp-block-heading">&#8216;My Own Father&#8217;</h2>
OP said he had explicitly warned his parents to keep quiet. &#8220;My own father.. ugh! I even specifically told them both to keep shut, but they&#8217;re old,&#8221; he said. &#8220;It&#8217;s my own damn fault for breaking rule No. 1.&#8221;
Living with his parents has made the secret harder to protect. &#8220;Hard to not tell them when I live in the same house,&#8221; he explained. &#8220;They see my room, and wall of screens, and constant double/triple-booked meetings.&#8221;
Even worse, he says his dad didn't just mention the number of jobs but talked about his son's total income. &#8220;My bi-weekly paycheck is almost people&#8217;s average yearly [income] here,&#8221; he added. That detail, in a small town, made it all the more damaging.
Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
The OP also mentioned he lives frugally and takes care of his parents. &#8220;We all live frugally—besides some <a href="https://www.benzinga.com/startups/24/08/40541567/100-hour-weeks-worth-it-for-this-gen-xer-secretly-working-multiple-jobs-and-earning-150-000-the-answ">splurging on trips</a> every now and then. I have <a href="https://www.benzinga.com/news/25/01/43346851/surprisingly-feasible-software-engineer-shares-how-a-175k-second-job-helped-him-save-20k-in-just-two-months">everything paid off</a>, and we're not rich, but comfortable.&#8221;
<h2 class="wp-block-heading">Advice From Others: Lie, Deflect, Deny</h2>
The overemployment community immediately rallied around him, sharing similar stories and advice. Some suggested he pretend he quit or got laid off. Others recommended saying he was just exaggerating or joking.
&#8220;Tell him you decided to quit and it was too much,&#8221; one person advised. &#8220;Or tell him you got caught. Whatever you do, tell him you don't OE anymore.&#8221;
&#8220;My mom swears up and down she can keep a secret,&#8221; another added. &#8220;But I listen to her blabbing other people's business all the damn time. So… yeah, can't trust her with OE.&#8221;
For one person, it&#8217;s straightforward: &#8220;A secret is only a secret when one person knows. When two people know it&#8217;s gossip.&#8221;
See Also: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
<h2 class="wp-block-heading">Broke Or Boasting?</h2>
Some called out the original poster for claiming to be broke despite making $20,000 a month. &#8220;Bro, under what circumstances were you saying you were broke?&#8221; one asked. &#8220;You've posted in this sub making $20K/month from 3 jobs. Am I crazy for thinking you deserve the anxiety if you're going around telling people you're broke making $240K/year?&#8221;
In hindsight, the lesson is obvious: overemployment thrives on discretion. Even well-meaning loved ones can unintentionally jeopardize a setup that relies on secrecy. The original poster now knows firsthand that one loose comment can snowball into a real threat.
As one person said, &#8220;If you can't keep your own secret, how can you expect someone else to?&#8221;&nbsp;
Read Next: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Image: Shutterstock

Personal Finance

He Confessed To His Dad About Working Multiple High-Paying Jobs. Now That His Dad Outed Him 'Feels Like The Grenade Trigger Has Been Pulled'

Fly-E Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 35.2%

Wells Fargo analyst Ken Gawrelski maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Equal-Weight and raises the price target from $13 to $14.

LYFT

Wells Fargo Maintains Equal-Weight on Lyft, Raises Price Target to $14

Wells Fargo analyst Ken Gawrelski maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Equal-Weight and raises the price target from $149 to $178.

EXPE

Wells Fargo Maintains Equal-Weight on Expedia Group, Raises Price Target to $178

Contracts

Press Releases

K Wave Media, Inc. (Nasdaq: KWM) ("K Wave" or the "Company") Announces entering into a securities purchase agreement for $500 Million Equity Purchase Facility to Support Bitcoin Treasury Strategy

Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion

K Wave Media Announces Upcoming Content Lineup and Expands Bitcoin Strategic Reserve Plan

AMZN

BAOS

CLRB

COST

MODV

NCEW

SNYR

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

Cineverse

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Eventbrite

Gaia

Global Mofy AI Limited - Class A Ordinary Shares

Global Mofy AI

iQIYI

Kuke Music Holding Limited American Depositary Shares (each representing ten (10) Class A Ordinary Shares)

Comments

K Wave Media

Noticias

Últimas noticias sobre K Wave Media (NASDAQ:KWM) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL